Department of Ophthalmology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
Transl Vis Sci Technol. 2022 Feb 1;11(2):1. doi: 10.1167/tvst.11.2.1.
Impaired ocular blood flow has been associated with the etiopathogenesis of glaucoma. Topical brimonidine lowers intraocular pressure, a major glaucoma risk factor. However, brimonidine's influence on retinal blood flow remains to be fully elucidated. Our aim was to compare the effect of topical brimonidine and brinzolamide administration on retinal blood flow velocity in second and third order vessels in healthy adults using the retinal function imager.
In 10 healthy probands between 23 and 32 years of age, one eye was randomly selected to receive 2 treatment rounds with 3 single doses of brimonidine 2 mg/mL and brinzolamide 10 mg/mL at 12-hour intervals each. The fellow eyes served as intra-individual controls. Immediately before the first drop and 2 hours after the last drop of each treatment round, all subjects were examined, including Goldmann tonometry, Pascal tonometry, assessment of retinal blood flow velocity using the retinal function imager, as well as blood pressure and pulse measurements.
Intraocular pressure decreased significantly in treated eyes while remaining stable in control eyes, indicating reliable application of brimonidine and brinzolamide drops. In contrast, retinal blood flow velocities did not demonstrate any significant differences between groups after both treatment rounds.
Neither brimonidine nor brinzolamide appear to alter retinal blood flow velocity in a clinically relevant manner. The slight velocity changes detected in our study are likely physiologic fluctuations. Our findings do not support the rationale of a detrimental effect of topical brimonidine on ocular blood flow and hence brimonidine may be further administered for lowering intraocular pressure with the appropriate caution. However, our study is strongly limited by the small sample size and, thus, further research with larger cohorts of healthy volunteers and patients with glaucoma is needed to confirm the results.
The study provides information about the effect of the topically administered antiglaucoma medications brimonidine and brinzolamide on the ocular blood flow and its regulation. The findings indicate that beside the lowering of IOP there is no evidence for an additional effect on the development of glaucoma.
眼血流受损与青光眼的病因发病机制有关。局部应用溴莫尼定可降低眼内压,这是青光眼的一个主要危险因素。然而,溴莫尼定对视网膜血流的影响仍有待充分阐明。我们的目的是使用视网膜功能成像仪比较局部应用溴莫尼定和布林佐胺对健康成年人第二和第三级血管视网膜血流速度的影响。
在 10 名年龄在 23 岁至 32 岁之间的健康受试者中,每只眼随机选择接受 2 轮治疗,每 12 小时用 3 次单剂量 2mg/ml 溴莫尼定和 10mg/ml 布林佐胺治疗。对侧眼作为个体内对照。在第一轮治疗的第一滴之前和第二轮治疗的最后一滴后 2 小时,对所有受试者进行检查,包括 Goldmann 眼压计、Pascal 眼压计、使用视网膜功能成像仪评估视网膜血流速度以及血压和脉搏测量。
治疗眼的眼内压显著下降,而对照眼的眼内压保持稳定,表明溴莫尼定和布林佐胺滴眼剂的应用可靠。然而,两轮治疗后,两组之间的视网膜血流速度均无显著差异。
溴莫尼定和布林佐胺均未以临床相关的方式改变视网膜血流速度。我们研究中检测到的轻微速度变化可能是生理性波动。我们的研究结果不支持局部应用溴莫尼定会对眼血流产生不利影响的理论,因此可以谨慎地进一步应用溴莫尼定降低眼内压。然而,我们的研究受到样本量小的严重限制,因此需要进一步研究有更大的健康志愿者和青光眼患者队列,以证实这些结果。
眼血流受损与青光眼的病因发病机制有关。局部应用溴莫尼定可降低眼内压,这是青光眼的一个主要危险因素。然而,溴莫尼定对视网膜血流的影响仍有待充分阐明。我们的目的是使用视网膜功能成像仪比较局部应用溴莫尼定和布林佐胺对健康成年人第二和第三级血管视网膜血流速度的影响。
在 10 名年龄在 23 岁至 32 岁之间的健康受试者中,每只眼随机选择接受 2 轮治疗,每 12 小时用 3 次单剂量 2mg/ml 溴莫尼定和 10mg/ml 布林佐胺治疗。对侧眼作为个体内对照。在第一轮治疗的第一滴之前和第二轮治疗的最后一滴后 2 小时,对所有受试者进行检查,包括 Goldmann 眼压计、Pascal 眼压计、使用视网膜功能成像仪评估视网膜血流速度以及血压和脉搏测量。
治疗眼的眼内压显著下降,而对照眼的眼内压保持稳定,表明溴莫尼定和布林佐胺滴眼剂的应用可靠。然而,两轮治疗后,两组之间的视网膜血流速度均无显著差异。
溴莫尼定和布林佐胺均未以临床相关的方式改变视网膜血流速度。我们研究中检测到的轻微速度变化可能是生理性波动。我们的研究结果不支持局部应用溴莫尼定会对眼血流产生不利影响的理论,因此可以谨慎地进一步应用溴莫尼定降低眼内压。然而,我们的研究受到样本量小的严重限制,因此需要进一步研究有更大的健康志愿者和青光眼患者队列,以证实这些结果。